Association Between Opioid Analgesics and Suicide Attempts: A Nationwide French Case-Crossover Study
CNS Drugs · 2025
DOI: 10.1007/s40263-025-01221-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift CNS Drugs, 2025. Verfasst von Bénédicte Nobile und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Psychiatry and Post-Acute Care, CHU Montpellier, Montpellier, France. benedicte.nobile@gmail.com. Hauptthemen laut MEDLINE: Analgesics, Opioid, Suicide, Attempted. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Centre Hospitalier Régional Universitaire de Montpellier.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: The rising prescription rates and opioid-related harms in France highlight the need for local data. Evaluating this association may help identify vulnerable subgroups and guide safer prescribing practices. This study aimed to assess the association between opioid analgesic dispensation and the risk of suicide attempt in the French population. Secondary objectives included evaluation of a dose-response relationship and examination of the potential additive effects of co-prescriptions with benzodiazepines or gabapentinoids. METHODS: We conducted a nationwide, population-based case-crossover study using data from the French National Health Insurance Database (Système National des Données de Santé, SNDS), covering 98.8% of the French population. Adults aged 18 years or older who were hospitalized for a first suicide attempt between 1 January 2013 and 31 December 2020, and who had received at least one opioid analgesic dispensation in the preceding year (excluding buprenorphine and methadone) were included. Opioid analgesic exposure during the 84 days before the attempt was compared with three earlier 84-day control periods. RESULTS: Among 158,400 patients (mean age 47.0 years; 64.0% women), opioid analgesic dispensation was associated with a higher risk of suicide attempt (odds ratio [OR] = 1.26; 95% confidence interval 1.25-1.28). The risk was greater for strong opioid analgesics (OR = 1.73) and higher morphine-equivalent doses. Co-prescription with benzodiazepines or gabapentinoids further increased risk. CONCLUSIONS: Opioid analgesic use, especially at higher doses or in combination with benzodiazepines or gabapentinoids, was associated with an increased risk of suicide attempt. Clinical vigilance is warranted when prescribing these medications. TRIAL REGISTRATION: NCT04211077, registered 3 January 2020 (retrospectively registered).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emergency Psychiatry and Post-Acute Care, CHU Montpellier, Montpellier, France. benedicte.nobile@gmail.com.
- IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France. benedicte.nobile@gmail.com.
- IGF, Hôpital La Colombière, 39 Avenue Charles Flahault, BP 34493, 34093, Montpellier cedex, France. benedicte.nobile@gmail.com.
- Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
- Department of Emergency Psychiatry and Post-Acute Care, CHU Montpellier, Montpellier, France.
- IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.
ORCID-Profile: Bénédicte Nobile
Förderung
- Centre Hospitalier Régional Universitaire de Montpellier
Zitieren
APA
Nobile, B., Nogue, E., Picot, M. C., Courtet, P., Chenaf, C., Authier, N., & Olié, E. (2025). Association Between Opioid Analgesics and Suicide Attempts: A Nationwide French Case-Crossover Study. CNS Drugs. https://doi.org/10.1007/s40263-025-01221-4
Vancouver
Nobile B, Nogue E, Picot MC, Courtet P, Chenaf C, Authier N, et al. Association Between Opioid Analgesics and Suicide Attempts: A Nationwide French Case-Crossover Study. CNS Drugs. 2025. doi:10.1007/s40263-025-01221-4
BibTeX
@article{Nobile2025,
author = {Nobile, Bénédicte and Nogue, Erika and Picot, M C and Courtet, Philippe and Chenaf, Chouki and Authier, Nicolas and Olié, Emilie},
title = {Association Between Opioid Analgesics and Suicide Attempts: A Nationwide French Case-Crossover Study},
journal = {CNS Drugs},
year = {2025},
doi = {10.1007/s40263-025-01221-4}
}
EUVIMED